TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models
Preprint in bioRxiv (January 2024)
The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.
Preprint in bioRxiv (January 2024)
Article in Frontiers in Oncology (September 2023)
Article in Scientific Reports (September 2023)